Abstract
To reduce virus infectivity in blood products, several methods were attempted. Selection and then screening of volunteer donors (HBsAg, anti-HIV Ab, anti-HBc Ab, anti-HCV Ab, ALAT) have reduced the likelihood of viral transmission. Despite all the screening tests and the purification methods used to produce therapeutic stable protein solutions, the best method for further reducing viral risks is the introduction of a viral inactivation step in the procedure. For albumin, pasteurization [[1]] on the final product has been found to be an effective way for viral sterilization and until now no case of hepatitis B has been attributed to pasteurized albumin. For coagulation factors, the first method used was the heating of concentrates in the lyophilised state [[2]] to kill HIV virus. Improvement has been achieved by including a solvent detergent method in the procedure to inactivate all viruses [[3]].
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Gellis S, Neefe J, Strong l, Janeway C, Scatchard G. Chemical, clinical and immunological studies on products of human plasma fractionation: Inactivation of virus of homologous serum albumin by means of heat. J Clin Invest 1948;27:239–44.
Hollinger JB, Dolano G, Thomas W, Gyorkey F. Reduction risk of hepatitis transmission by heat treatment of a human factor VIII concentrate. J Inf Dis 1984;150:250–64.
Horowitz B, Wiebe ME, Lippin A, Stryker MH. Inactivation of virus in labile blood derivates. I. Disruption of lipid-enveloped virus by tri/n/buthyl/phosphate detergent combinations. Transfusion 1985;25:216–9.
Horowitz B. Virus sterilization of plasma protein by treatment with solvent detergent mixtures. A summary. Thromb Res 1987;48(supp.VII):51 (abstract).
Biggs R, Evelin S, Richards G. The assay of anti-haemophilic globulin activity. Br J Haemat 1955;1:20–34.
Soulier JP, Larrieu MS. Etude analytique des temps de Quick allongés. Dosage de prothrombine, de proconvertine et de pro-accélérine. Sang 1982;23:549–59.
Odegard OR, Lie M, Abilgaard U. Heparin cofactor activity measured with an amidolytic method. Thromb Res 1975;6:287–94.
Howard MA, Firkin BG. Ristocetin: A new tool in the investigation of platelet aggregation. Thromb Diath Haemorrh 1971;26:362–9.
Clauss A. Gerinnungs physiologische Schnellmethode 2 in Bestimmung des Fibrinogens. Acta Haemat 1975;17:237–46.
Vinazzer H. Comparison between two concentrates with factor VIII inhibitor bypassing activity. Thromb Res 1982;26:21–9.
Martinoli JL, Doussin G, Nigham F. Automatisation de l’étude de l’hémostase et de la fibrinolyse par les substrats chromogéniques. Nouv Rev Franç Hématol 1981;23(supp.):L (abstract Proc. VIe CSFG, Avignon).
Kingdon HS, Lundblad ML, Veltkamp JJ, Amonson DL. Potentially thrombogenic materials in factor IX concentrates. Thromb Diath Haemorrh 1975;33:617–31.
Wessler S, Reiner S, Sheps MC. Biological assay of a thrombosis inducing activity in human serum. J Appl Phys 1959;14:943–53.
Gornall A, Bardawill CH, David M. Determination of serum protein by means of the biuret reaction. J Biol Chem 1949;177:751–66.
Elson EC, Ivor L, Gochman N. Substitution of a non hazardous chromogen for benzidine in the measurement of plasma haemoglobin. Am J Clin Path 1978;69:354.
Thomas LLM, Sturck A, Kahle LH, ten Cate JW. Quantitative endotoxin determination in blood with a chromogenic substrate. Clin Chem 1981;116:63–8.
International Forum. What are the critical factors in the production and quality control of frozen plasma intended for direct transfusion or for fractionation to provide medically needed labile coagulation factors? Vox Sang 1983;44:246–59.
Carlebjork G, Blombäck M, Pihlstedt P. Freezing of plasma and recovery of factor VIII. Transfusion 1986;26/2:159–62
Prodouz KN, Fratantoni JC, Boone EJ, Booner RF. Use of laser UV for inactivation of virus in blood products. Blood 1987;70:589–92.
Mathews JL, Newman JT, Sogandares-Bernal F, et al. Photodynamic therapy of viral contaminants with potential for blood banking application. Transfusion 1988;28:80–3.
Yoshiaki H, Shinsi H, Sumunu K, et al. A novel method for removal of human immunodeficiency virus: Filtration with porous polymeric membranes. Vox Sang 1989;56:230–6.
Hiemstra H, Tersmette M, Vos H, Over J, van Berkel MP, Debree H. Inactivation of human immunodeficiency virus by gamma radiation and its effect on plasma and coagulation factors. Transfusion 1991;31:32–9.
Horowitz B, Piet PJ, Prince AM, Edwards CA, Lippin A, Walakovits ML. Inactivation of lipid enveloped viruses in labile blood derivates by unsaturted fatty acids. Vox Sang 1988;54:14–20.
Piet MPJ, Chin S, Prince AM, Brotman B, Cundell AM, Horowitz B. The use of tri-n-butyl phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma’s subsequent fractionation. Transfusion 1990;30:591–8.
Horowitz B, Chin S, Prince AM, Brotman B, Pascual D, Williams B. Preparation and characterization of S/D-FFP, a virus sterilized “fresh frozen plasma”. Thromb Haem 1991;65:1163 (abstract).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Piquet, Y. et al. (1992). An Improvement in the Supply of Safe Blood: Virus Inactivated Plasma Prepared in the Blood Bank. In: Smit Sibinga, C.T., Das, P.C., Cash, J.D. (eds) Transfusion Medicine: Fact and Fiction. Developments in Hematology and Immunology, vol 27. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3504-1_22
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3504-1_22
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6554-9
Online ISBN: 978-1-4615-3504-1
eBook Packages: Springer Book Archive